Friday, December 14, 2018 11:31:26 AM
Good presentation. One more small piece of data that corroborates the Pluristem story. Perhaps the implications of success in CLI can be broadened to include a multitude of occlusive diseases... hmm, maybe CLI is a pretty good indication to start with!
The money issue is something we have to look at, but my feeling is that as the evidence of efficacy keeps coming in, the ability of the company to raise funds will improve substantially. The challenge for Pluristem is no different than any other small biotech, success in the clinic will translate into support from partnerships, grants and other means. I don't think it should be a major worry.
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM